T
Therini Bio
A biotechnology company dedicated to the research and development of novel therapeutics for the treatment of neuroinflammatory diseases due to vascular dysfunction
About Therini Bio
Therini Bio is a clinical-stage biotechnology company focused on the development of fibrin-targeting immunotherapies. The company's primary area of research is neuroinflammation, with a specific interest in diseases driven by vascular dysfunction. Therini Bio's leading product candidate, THN391, is a monoclonal antibody that has undergone Phase 1a trials for the treatment of neurodegenerative diseases.
The company's therapeutic approach is centered on the idea that toxic fibrin deposits trigger inflammation cascades that contribute to a variety of illnesses. By targeting fibrin, Therini Bio aims to halt chronic neuroinflammation and subsequent neuronal damage. The company was founded in 2016 and is headquartered in South San Francisco, California.
Therini Bio operates within the biotechnology sector, a market characterized by high research and development costs and long product development timelines. The company's business model is typical of a clinical-stage biotech, involving the discovery and development of new therapeutics with the ultimate goal of commercialization, potentially through partnerships with larger pharmaceutical companies. The company's financial success is contingent on the successful clinical development and regulatory approval of its product candidates.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- South San Francisco, United States
- Employees
- 15
- Open positions
- None listed
- Dealroom signal
- 91.2/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | May 2025 | $39M | $156M | Dementia Discovery Fund · MRL Ventures · Dolby Family Ventures · SV Health Investors | ↗ |
| SERIES AOther financing | Apr 2023 | $36M | $144M | Merck & Co. · Sanofi Ventures · Eli Lilly · MRL Ventures | ↗ |
Growth signals
Latest recorded traffic for Therini Bio is 840 monthly website visits, down 30% over the last three months. Therini Bio's team grew 36.4% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed6 investors entered at this stage
Dolby Family Ventures
SV Health Investors
Dementia Discovery Fund
MRL Ventures
Sanofi Ventures
Foundation for a Better World
Series A5 investors entered at this stage
Merck & Co.
Eli Lilly
Alzheimer's Drug Discovery Foundation
Apollo Health Ventures
Angelini Ventures
Other known investors3 additional known investors
Gladstone Institutes
QB3
University of California, San Diego
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Therini Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Therini Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.